



## Review

# Coronary artery disease and depression

Michael J. Zellweger<sup>a\*</sup>, Remo H. Osterwalder<sup>a</sup>, Wolf Langewitz<sup>b</sup>,  
Matthias E. Pfisterer<sup>a</sup>

<sup>a</sup>Cardiology Department, University Hospital, Basel, Switzerland

<sup>b</sup>Psychosomatic Department, University Hospital, Basel, Switzerland

Received 4 April 2003; accepted 11 September 2003

## KEYWORDS

Coronary artery disease;  
Depression;  
Prognosis;  
Antidepressant therapy

Coronary artery disease (CAD) as well as depression are both highly prevalent diseases. Both cause a significant decrease in quality of life for the patient and impose a significant economic burden on society. There are several factors that seem to link depression with the development of CAD and with a worse outcome in patients with established CAD: worse adherence to prescribed medication and life style modifications in depressive patients, as well as higher rates in abnormal platelet function, endothelial dysfunction and lowered heart rate variability. The evidence is growing that depression per se is an independent risk factor for cardiac events in a patient population without known CAD and also in patients with established diagnosis of CAD, particularly after myocardial infarction. Treatment of depression has been shown to improve patients' quality of life. However, it did not improve cardiovascular prognosis in depressed patients even though there is open discussion about the trend to better outcome in treated patients. Large scale clinical trials are needed to answer this question. Selective serotonin reuptake inhibitors seem to be preferable to tricyclic antidepressants for treatment of depressive patients with comorbid CAD because of their good tolerability and absence of significant cardiovascular side effects. *Hypericum perforatum* (St. John's wort), an increasingly used herbal antidepressant drug should be used with caution due to severe and possibly dangerous interaction with cardioactive drugs.

© 2003 The European Society of Cardiology. Published by Elsevier Ltd. All rights reserved.

## Introduction

Recently new risk factors for coronary artery disease (CAD) have been identified, among them emotional distress and depression.<sup>1–5</sup> Taking into account that lifetime prevalence of depression is as high as 17%,<sup>6</sup> it is not surprising that CAD and depression are often comorbid conditions. Both of them cause a significant decrease in quality of life for the patient and impose a significant economic burden on society. The association of depression and CAD has been noted already many years ago. In the mid 19th century a paper about 'nervous and

sympathetic palpitations of the heart' was published.<sup>1</sup> This publication was followed by numerous papers describing the concept of neurologically based, or 'neurasthenic', cardiac disorders. In 1910, Sir William Osler described his typical patient with angina pectoris as 'a man whose engine is always set full speed ahead' and called his patients with cardiac disease 'worriers'.<sup>7</sup>

## Depression and CAD as comorbid conditions

Major depression is a highly prevalent and disabling mental disorder that is under-diagnosed and under-treated.<sup>6,8</sup> High rates of disease-related disability, and relapse or recurrence are common.<sup>9,10</sup> Major depression is associated with as much physical and social dysfunction as many other common medical illnesses. Similarly, CAD

\* Correspondence to: Michael J. Zellweger, MD, Department of Cardiology, University Hospital, Petersgraben 4, CH-4031 Basel, Switzerland. +41 61 265 5473; fax: +41 61 265 4598

E-mail address: mzellweger@uhbs.ch (M.J. Zellweger).

is highly prevalent in western populations affecting men and women with increasing age.<sup>11,12</sup> Social dysfunction is twice as high in patients with advanced CAD and depression as in patients with either condition alone.<sup>13–15</sup>

Depression can reliably be diagnosed by psychometric scales and standardized clinical interviews.<sup>16–19</sup> The typical features are the presence of depressed mood and markedly decreased interest in all activities, persisting for at least 2 weeks and accompanied by at least four of the following additional symptoms: changes in appetite, sleep disturbances, fatigue, psychomotor retardation or agitation, feelings of guilt or worthlessness, problems concentrating, and suicidal thoughts.<sup>4</sup> Various well structured questionnaires have been used and validated in the screening process such as the Hamilton Rating Scale for depression,<sup>16</sup> the recent life change questionnaire,<sup>20</sup> and the Beck Depression Inventory.<sup>17,18</sup> In addition, short forms of questionnaires are available which screen for depression and other psychiatric disorders including mood, anxiety, alcohol, eating, and somatoform disorders.<sup>19,21</sup> It is important to utilize these simple validated questionnaires to diagnose depression in primary care settings.

## Depression, CAD and outcome

### Population without known CAD

Many early studies evaluating the interaction of CAD and depression were secondary analyses of population-based databases and have to be interpreted with caution. Nonetheless, several studies suggest an interaction between depression and the development of CAD after adjustment for traditional cardiovascular risk factors.<sup>22</sup> Relative risk for myocardial infarction in patients with depressive symptoms versus non-depressive patients within the same cohort ranged from 1.5 (95% CI 1.0–2.3) to 4.5 (95% CI 1.7–12.4).<sup>23–27</sup> An increased risk for CAD was not only described in patients with major depression but also in those with minor depressive symptoms and dysphoria.<sup>23,27</sup> In a cohort of 2832 subjects who participated in the National Health Examination Follow-up Study (mean follow-up=12.4 years) and who had no history of CAD or serious illness at baseline, 11% had depressed affect; 10.8% reported moderate hopelessness, and 2.9% reported severe hopelessness. Depressed affect and hopelessness were more common among women, blacks, and persons who were less educated, unmarried, smokers, or physically inactive. After adjustment for demographic and risk factors patients with depressed affect and moderate as well as severe levels of hopelessness had a relative risk to suffer fatal CAD of 1.5 (95% CI 1.0–2.3); 1.6 (95% CI=1.0–2.5) and 2.1 (95% CI=1.1–3.9), respectively. Depressed affect and hopelessness were also associated with an increased risk of non-fatal CAD.<sup>23</sup> Another report in 730 patients showed that significant depression was associated with relative risks of 1.71 ( $P=0.005$ ) and 1.59 ( $P<0.001$ ) for myocardial infarction and deaths from all causes, respectively after adjustment for baseline variables.<sup>26</sup>

These findings were confirmed by several prospective studies. The Precursors study evaluated 1190 male medical students who were followed up for 40 years.<sup>28</sup> The cumulative incidence of clinical depression was 12%. Men who reported clinical depression were at significantly greater risk for subsequent CAD and myocardial infarction than men without depression, the relative risk being 2.12 (95% CI 1.24–3.63) and 2.12 (95% CI 1.11–4.6), respectively. Of note, the increased risk associated with clinical depression was present even for myocardial infarction occurring 10 years after the onset of the first depressive episode. The authors concluded that clinical depression appeared to be an independent risk factor for CAD for several decades after the onset of clinical depression.<sup>28</sup> In The Cardiovascular Health Study evaluating 5201 subjects with a follow-up of 6 years, high levels of depressive symptoms were an independent risk factor for mortality in community-residing older adults. The authors hypothesized that motivational depletion which is consistent with vital exhaustion and decreased emotional vitality may be a key underlying mechanism for the depression-mortality effect.<sup>29</sup>

### Interaction of depression and known CAD

In patients with angiographically proven CAD and no evidence of myocardial infarction or unstable angina the prevalence of depression was approximately 18% in one study.<sup>30</sup> In patients following acute myocardial infarction, up to 25% had severe, often recurrent major depression, while 27–65% manifested symptoms diagnostic of either major or minor depression.<sup>1,25,26,31,32</sup> The evidence that depression affects prognosis in patients with CAD, especially in patients after myocardial infarction is growing: reported relative risks for adverse outcome (mainly cardiac death) range from 2.5 to 5.7.<sup>33–42</sup> In addition to the mortality risk associated with post-myocardial infarction depression, increased health care costs linked to both readmission and out-patient contact among depressed patients who survived the first year after infarction have been observed.<sup>43</sup>

Of note, not only full blown major depression accounted for worse outcome: multivariate analysis in 222 patients with prior myocardial infarction demonstrated that depressive symptoms, anxiety, and history of major depression each had an impact on outcome independent of each other.<sup>34</sup> This finding was confirmed by other studies in patients after myocardial infarction in which mortality rates increased as a function of the degree of depressive symptoms.<sup>38,44</sup>

Impact of major depression on prognosis was as relevant as left ventricular dysfunction (Killip class) and history of previous myocardial infarction<sup>33</sup> and proved to be a significant predictor of 1-year cardiac mortality for women as well as for men independent of other post-myocardial infarction risks.<sup>35</sup> Recently, it has been suggested that depression had a similar impact on prognosis in patients with unstable angina as in patients post myocardial infarction.<sup>37</sup>

A higher prevalence of ventricular tachycardia during 24-h Holter monitoring among patients with CAD and

depression than among CAD patients without depression has been noted which may contribute to the explanation of the increased risk for cardiac mortality in depressed patients with CAD.<sup>45</sup>

In patients with coronary artery bypass graft surgery, it has been shown that depression diagnosed before surgery was related to higher hospital re-admission rates<sup>46</sup> and was an independent risk factor for cardiac events after surgery,<sup>39,47</sup> suggesting that positive emotions may promote better recovery.<sup>48</sup>

In summary, there is considerable evidence suggesting that depression and comorbid CAD may lead to an increased risk of death, regardless of which illness occurred first.<sup>6</sup> The most prominent finding is the increased mortality in patients with depression after myocardial infarction.

### Pathophysiologic factors possibly linking depression and CAD

Several studies indicated that depression may have behavioural and direct pathophysiologic effects on CAD. Depression is associated with non-adherence to risk factor modification in many medical conditions,<sup>49–52</sup> such as smoking cessation,<sup>53,54</sup> poor patient compliance,<sup>55,56</sup> e.g. poor glycaemic control in diabetic patients<sup>57</sup> and poor adherence to prescribed medication in general.<sup>56</sup> In addition direct pathophysiologic effects linking depression to CAD have been postulated.

Abnormal platelet function,<sup>58–62</sup> including increased platelet reactivity, increased levels of platelet factor 4 and  $\beta$ -thromboglobulin, increased platelet reactivity to serotonin and decreased platelet reactivity to adenosine diphosphate<sup>59</sup> have been discussed. In addition, and in contrast to paroxetine administration, nortriptyline did not reverse increased levels of platelet factor 4 and  $\beta$ -thromboglobulin measures of platelet activation in patients with depression and CAD.<sup>60</sup>

It has also been hypothesized that hypercortisolemia and elevated levels of corticotropin-releasing factor may be as relevant as additional pathophysiologic mechanisms of depression linked to CAD<sup>4</sup> as well as  $\Omega$ -3 fatty acid deficiency and elevated homocysteine levels.<sup>64</sup>

Furthermore, endothelial dysfunction has been reported in depressive patients. Fifteen patients who met the criteria for 'major depressive disorder' and lacked conventional risk factors for CAD were compared to matched control subjects with respect to brachial artery flow-mediated vasodilation.<sup>63</sup> Results showed that the only independent predictor of the amount of reactive hyperaemia was presence or absence of depression indicating that major depression in the absence of other conventional risk factors is associated with abnormal peripheral artery endothelial function.

In addition, patients with anxiety and depressive disorders have been shown to have reduced heart rate variability.<sup>65–68</sup> This finding may have important prognostic implications because low heart rate variability is a powerful predictor of sudden cardiac death.<sup>69,70</sup> Even in healthy subjects, depressed mood was related to the magnitude of decrease in parasympathetic cardiac con-

rol during stressors.<sup>71</sup> In patients after a recent myocardial infarction with evidence of depression, four indices of heart rate variability were significantly reduced compared to patients without depression<sup>66</sup> indicating that greater autonomic dysfunction as reflected by decreased heart rate variability might be a plausible mechanism linking depression to increased cardiac mortality in post-myocardial infarction patients.<sup>66</sup> Finally, a direct association between the severity of depressive symptoms and the modulation of cardiovagal activity was found.<sup>65</sup>

Thus, abnormal platelet function, endothelial dysfunction, and reduced heart rate variability have been identified as possible links between depression and CAD, however, more research in large scale clinical trials is needed to confirm these interrelationships and to assess their changes after antidepressant treatment.

### Treatment of depression in patients with CAD

In patients with CAD, several small clinical trials suggest that cognitive-behavioural therapy successfully reduced anxiety and depression, and thus facilitated the modification of cardiac risk factors.<sup>72–74</sup> Data of the Enhancing Recovery in Coronary Heart Disease (ENRICH) trial have been published recently.<sup>75,76</sup> This randomized controlled clinical trial evaluated 2481 patients with evidence of depression after myocardial infarction who either underwent treatment for depression (cognitive behavioural therapy) or usual care. Despite the treatment group's improvements in depression and social support, there was no significant difference in event-free survival (mortality and recurrent infarction) after an average follow-up of 29 months, between usual care (75.9%) and psychosocial intervention (75.8%).

However, several studies suggest that depressive patients with CAD benefit from cardiac rehabilitation programmes by improving coping skills and self image, reducing biological risk factors such as social isolation and smoking, by providing emotional support, and improving quality of life scores,<sup>1,77–79</sup> regardless of patient age and gender.<sup>80,81</sup> Unfortunately, drop-out rates from rehabilitation programmes are higher in depressive patients than in non-depressive patients.<sup>82</sup> Therefore, depressive patients with CAD should be encouraged to participate in cardiac rehabilitation programmes!

### Medical therapy of depression

For many years, pharmacologic treatment for patients with depression and stable CAD was based on tricyclic antidepressive agents (TCA), such as amitriptyline, imipramine, nortriptyline, desipramine, and doxepin. TCA's have several adverse effects that complicate their use in patients with cardiac disease.<sup>1</sup> Tricyclic antidepressive agents cause orthostatic hypotension, which may result in haemodynamic instability, especially in patients with conduction system disease and congestive heart failure.<sup>1</sup> Furthermore, TCA's have anticholinergic

effects and a high potential for drug interaction. TCA's also have significant anti-arrhythmic activity and can be classified as type IA anti-arrhythmic agents,<sup>83–85</sup> but also show arrhythmogenic potential.<sup>86,87</sup>

In contrast, selective serotonin reuptake inhibitors (SSRI) have only minimal cardiac side effects: the only effect of citalopram on ECG findings was a small reduction in heart rate (less or equal to 8 beats per minute). There were no significant effects on PQ, QRS, or QTc intervals, indicating that citalopram has no effect on cardiac conduction and repolarization during short- or long-term treatment.<sup>88</sup>

In a study ( $n=81$ ) comparing paroxetine (aSSRI) and nortriptyline (a TCA) both treatments were similarly effective in reducing depressive symptoms, but paroxetine was better tolerated than nortriptyline and less likely to produce cardiovascular side effects.<sup>89</sup> In patients with recent myocardial infarction or unstable angina and without other life-threatening medical conditions sertraline has been shown to be a safe and effective treatment for recurrent depression.<sup>90</sup>

Another study with paroxetine demonstrated that reduced panic attacks were paralleled by increased parasympathetic activity but preserved baroreflex response. The authors concluded that potential benefits of selective serotonin reuptake inhibitors in decreasing cardiac mortality might be achieved by the increase of heart rate variability.<sup>91</sup> In depressed survivors of acute myocardial infarction sertraline facilitated the rate of recovery of heart rate variability, a recognized predictor of clinical outcome.<sup>92</sup>

To assess the risk of myocardial infarction, 2247 patients who received at least one prescription for an antidepressant were compared with 52750 subjects who did not. Patients were compared with respect to antidepressant treatments they received: TCA's, SSRI's, and others. Over a follow-up of 4.5 years, antidepressant users had a more than twofold risk to suffer a myocardial infarction (relative risk 2.2 (95% CI 1.3 to 3.7)) when compared with nonusers. Patients using TCA's and SSRI's had relative risks of 2.2 (95% CI 1.2 to 3.8) and 0.8 (95% CI 0.2 to 3.5), respectively, suggesting an association between use of TCA's and increased risk to suffer myocardial infarction. In SSRI's, there was no such correlation.<sup>93</sup> However, in another study, SSRI exposure did not substantially decrease the risk of developing first-time acute myocardial infarction in patients free of other factors predisposing to CAD.<sup>94</sup>

Two large prospective trials are currently running and should provide more insight into the interaction of depression, CAD, treatment and prognosis.

The Myocardial Infarction and Depression-Intervention Trial (MIND-IT) will show in 2140 patients admitted for myocardial infarction, whether antidepressant treatment of post-myocardial infarction depression, preferably with mirtazapine, can improve cardiac prognosis.<sup>95</sup> In this regard, the Sertraline Antidepressant Heart Attack Randomized Trial (SADHART Study) has not only provided safety data but also shown a trend to a better outcome in post-myocardial infarction patients who were randomized to treatment with sertraline compared with placebo.<sup>90</sup>

In summary, since quality of life in CAD patients with depression is decreased, screening for psychosocial risk factors and antidepressant therapy may be indicated, although to date there is only limited data from randomized trials whether this treatment effectively reduces morbidity and mortality. Even if survival is not improved by antidepressive therapy, more clinical trials are needed to define the optimal management of patients with CAD and depression.<sup>96,97</sup>

## Herbal medication

*Hypericum perforatum* (St. John's wort) has become a popular alternative treatment for depression and several randomized clinical trials have been published; however with conflicting results.<sup>98–102</sup> It is noteworthy that several drug interactions of cardioactive drugs with St. John's wort were recently published.<sup>103,104</sup> These interactions are probably due to the induction of cytochrome P450 isoenzymes CYP3A4, CYP2C9, CYP1A2 and the transport protein P-glycoprotein by constituent(s) in St. John's wort. The degree of induction is unpredictable due to factors such as the variable quality and quantity of constituent(s) in St. John's wort preparations. In addition, possible pharmacodynamic interactions with SSRI's and serotonin (5-HT(1d)) receptor-agonists such as triptans used to treat migraine were identified. These interactions are associated with an increased risk of adverse reactions.<sup>105</sup> St John's wort also can endanger the success of organ transplantations.<sup>106,107</sup> In summary, the growing use of herbal remedies has far exceeded the available information on their benefits, adverse effects and drug interactions.<sup>108,109</sup>

## Conclusions and implications

Coronary artery disease as well as depression are both highly prevalent diseases. Both of them cause a significant decrease in quality of life for the patient and impose a significant economic burden on society. The evidence is growing that depression per se is an independent risk factor to suffer a cardiac event. This has been shown in patients with as well as without known CAD. There are several behavioural and pathophysiologic factors that seem to link depression with development of CAD and with a worse outcome in patients with established diagnosis of CAD. Treatment of depression has been shown to improve quality of life of patients. There are also preliminary results suggesting a trend to better cardiovascular prognosis with antidepressive treatment in CAD patients. One may hypothesize that patients treated for their depression might better adhere to risk factor modifications, prescribed medications and rehabilitation programmes. Patients with known CAD and evidence of depression should therefore be evaluated for antidepressive therapy such as cognitive behavioural therapy, complex cardiac rehabilitation programmes, and pharmacologic treatment. Regarding pharmacologic treatment, SSRI's may be preferred for their good tolerability and absence of significant cardiovascular side effects. Furthermore, one should be aware of the

increasing use of herbal medications such as Saint John's wort which may cause severe and possibly dangerous drug interactions with cardioactive drugs.

## References

- Januzzi JL Jr, Stern TA, Pasternak RC et al. The influence of anxiety and depression on outcomes of patients with coronary artery disease. *Arch Intern Med* 2000;160:1913–21.
- Jiang W, Krishnan RR, O'Connor CM. Depression and heart disease: evidence of a link, and its therapeutic implications. *CNS Drugs* 2002;16:111–27.
- Kubzansky LD, Kawachi I. Going to the heart of the matter: do negative emotions cause coronary heart disease? *J Psychosom Res* 2000;48:323–37.
- Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. *Circulation* 1999;99:2192–217.
- Perlmutter JB, Frishman WH, Feinstein RE. Major depression as a risk factor for cardiovascular disease: therapeutic implications. *Heart Dis* 2000;2:75–82.
- O'Connor C M, Gurbel PA, Serebruany VL. Depression and ischemic heart disease. *Am Heart J* 2000;140:63–9.
- Osler W. The Lumleian lectures on angina pectoris. *Lancet* 1892;1:829–44.
- Nemeroff CB, Musselman DL, Evans DL. Depression and cardiac disease. *Depress Anxiety* 1998;8(Suppl 1):71–9.
- Wells KB, Stewart A, Hays RD et al. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. *JAMA* 1989;262:914–9.
- Wells KB, Burnam MA, Rogers W et al. The course of depression in adult outpatients. Results from the Medical Outcomes Study. *Arch Gen Psychiatry* 1992;49:788–94.
- Rickenbacher P, Pfisterer M. TIME has come to have a closer look at the management of cardiovascular disease in the elderly. *Eur Heart J* 2002;23:993–5.
- Stone NJ. The clinical and economic significance of atherosclerosis. *Am J Med* 1996;101:4A65–95.
- Judd LL, Schettler PJ, Akiskal HS. The prevalence, clinical relevance, and public health significance of subthreshold depressions. *Psychiatr Clin North Am* 2002;25:685–98.
- Keller MB, Klerman GL, Lavori PW et al. Long-term outcome of episodes of major depression. Clinical and public health significance. *JAMA* 1984;252:788–92.
- Keller MB, Boland RJ. Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression. *Biol Psychiatry* 1998;44:348–60.
- Hamilton M. Development of a rating scale for primary depressive illness. *Br J Soc Clin Psychol* 1967;6:278–96.
- Beck AT, Beamesderfer A. Assessment of depression: the depression inventory. *Mod Probl Pharmacopsychiatry* 1974;7:151–69.
- Beck AT, Rial WY, Rickels K. Short form of depression inventory: cross-validation. *Psychol Rep* 1974;34:1184–6.
- Spitzer RL, Williams JB, Kroenke K et al. Utility of a new procedure for diagnosing mental disorders in primary care. The PRIME-MD 1000 study. *JAMA* 1994;272:1749–56.
- Horowitz M, Schaefer C, Hiroto D et al. Life event questionnaires for measuring presumptive stress. *Psychosom Med* 1977;39:413–31.
- Sheehan DV, Lecrubier Y, Sheehan KH et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *J Clin Psychiatry* 1998;59(Suppl 20):22–33 quiz 34–57.
- Wulsin LR, Singal BM. Do depressive symptoms increase the risk for the onset of coronary disease? A systematic quantitative review. *Psychosom Med* 2003;65:201–10.
- Anda R, Williamson D, Jones D et al. Depressed affect, hopelessness, and the risk of ischemic heart disease in a cohort of U.S. adults. *Epidemiology* 1993;4:285–94.
- Aromaa A, Raitasalo R, Reunanen A et al. Depression and cardiovascular diseases. *Acta Psychiatr Scand Suppl* 1994;377:77–82.
- Barefoot JC, Helms MJ, Mark DB et al. Depression and long-term mortality risk in patients with coronary artery disease. *Am J Cardiol* 1996;78:613–7.
- Barefoot JC, Schroll M. Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. *Circulation* 1996;93:1976–80.
- Pratt LA, Ford DE, Crum RM et al. Depression, psychotropic medication, and risk of myocardial infarction. Prospective data from the Baltimore ECA follow-up. *Circulation* 1996;94:3123–9.
- Ford DE, Mead LA, Chang PP et al. Depression is a risk factor for coronary artery disease in men: the precursors study. *Arch Intern Med* 1998;158:1422–6.
- Schulz R, Beach SR, Ives DG et al. Association between depression and mortality in older adults: the Cardiovascular Health Study. *Arch Intern Med* 2000;160:1761–8.
- Carney RM, Rich MW, Tevelde A et al. Major depressive disorder in coronary artery disease. *Am J Cardiol* 1987;60:1273–5.
- Carney RM, Freedland KE, Sheline YI et al. Depression and coronary heart disease: a review for cardiologists. *Clin Cardiol* 1997;20:196–200.
- Bliven BD, Green CP, Spertus JA. Review of available instruments and methods for assessing quality of life in anti-anginal trials. *Drugs Aging* 1998;13:311–20.
- Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction. Impact on 6-month survival. *JAMA* 1993;270:1819–25.
- Frasure-Smith N, Lesperance F, Talajic M. The impact of negative emotions on prognosis following myocardial infarction: is it more than depression? *Health Psychol* 1995;14:388–98.
- Frasure-Smith N, Lesperance F, Juneau M et al. Gender, depression, and one-year prognosis after myocardial infarction. *Psychosom Med* 1999;61:26–37.
- Frasure-Smith N, Lesperance F, Gravel G et al. Social support, depression, and mortality during the first year after myocardial infarction. *Circulation* 2000;101:1919–24.
- Lesperance F, Frasure-Smith N, Juneau M et al. Depression and 1-year prognosis in unstable angina. *Arch Intern Med* 2000;160:1354–60.
- Lesperance F, Frasure-Smith N, Talajic M et al. Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms after myocardial infarction. *Circulation* 2002;105:1049–53.
- Pignay-Demaria V, Lesperance F, Demaria RG et al. Depression and anxiety and outcomes of coronary artery bypass surgery. *Ann Thorac Surg* 2003;75:314–21.
- Denollet J, Sys SU, Stroobant N et al. Personality as independent predictor of long-term mortality in patients with coronary heart disease. *Lancet* 1996;347:417–21.
- Denollet J, Brutsaert DL. Personality, disease severity, and the risk of long-term cardiac events in patients with a decreased ejection fraction after myocardial infarction. *Circulation* 1998;97:167–73.
- Welin C, Lappas G, Wilhelmson L. Independent importance of psychosocial factors for prognosis after myocardial infarction. *J Intern Med* 2000;247:629–39.
- Frasure-Smith N, Lesperance F, Gravel G et al. Depression and health-care costs during the first year following myocardial infarction. *J Psychosom Res* 2000;48:471–8.
- Bush DE, Ziegelstein RC, Tayback M et al. Even minimal symptoms of depression increase mortality risk after acute myocardial infarction. *Am J Cardiol* 2001;88:337–41.
- Carney RM, Freedland KE, Rich MW et al. Ventricular tachycardia and psychiatric depression in patients with coronary artery disease. *Am J Med* 1993;95:23–8.
- Saur CD, Granger BB, Muhlbaier LH et al. Depressive symptoms and outcome of coronary artery bypass grafting. *Am J Crit Care* 2001;10:4–10.
- Connerney I, Shapiro PA, McLaughlin JS et al. Relation between depression after coronary artery bypass surgery and 12-month outcome: a prospective study. *Lancet* 2001;358:1766–71.
- Scheier MF, Matthews KA, Owens JF et al. Optimism and rehospitalization after coronary artery bypass graft surgery. *Arch Intern Med* 1999;159:829–35.
- McDermott MM, Schmitt B, Wallner E. Impact of medication non-adherence on coronary heart disease outcomes. A critical review. *Arch Intern Med* 1997;157:1921–9.
- Horwitz RI, Viscoli CM, Berkman L et al. Treatment adherence and risk of death after a myocardial infarction. *Lancet* 1990;336:542–5.

51. Druss BG. Cardiovascular procedures in patients with mental disorders. *JAMA* 2000;**283**:3198–9.
52. Druss BG, Bradford DW, Rosenheck RA et al. Mental disorders and use of cardiovascular procedures after myocardial infarction. *JAMA* 2000;**283**:506–11.
53. Glassman AH, Helzer JE, Covey LS et al. Smoking, smoking cessation, and major depression. *JAMA* 1990;**264**:1546–9.
54. Covey LS, Glassman AH, Stetner F et al. A randomized trial of sertraline as a cessation aid for smokers with a history of major depression. *Am J Psychiatry* 2002;**159**:1731–7.
55. Ziegelstein RC, Fauerbach JA, Stevens SS et al. Patients with depression are less likely to follow recommendations to reduce cardiac risk during recovery from a myocardial infarction. *Arch Intern Med* 2000;**160**:1818–23.
56. Carney RM, Freedland KE, Eisen SA et al. Major depression and medication adherence in elderly patients with coronary artery disease. *Health Psychol* 1995;**14**:88–90.
57. Lustman PJ, Anderson RJ, Freedland KE et al. Depression and poor glycemic control: a meta-analytic review of the literature. *Diabetes Care* 2000;**23**:934–42.
58. Musselman DL, Tomer A, Manatunga AK et al. Exaggerated platelet reactivity in major depression. *Am J Psychiatry* 1996;**153**:1313–7.
59. Shimbo D, Child J, Davidson K et al. Exaggerated serotonin-mediated platelet reactivity as a possible link in depression and acute coronary syndromes. *Am J Cardiol* 2002;**89**:331–3.
60. Pollock BG, Laghrissi-Thode F, Wagner WR. Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. *J Clin Psychopharmacol* 2000;**20**:137–40.
61. Laghrissi-Thode F, Wagner WR, Pollock BG et al. Elevated platelet factor 4 and beta-thromboglobulin plasma levels in depressed patients with ischemic heart disease. *Biol Psychiatry* 1997;**42**:290–5.
62. von Kanel R, Mills PJ, Fainman C et al. Effects of psychological stress and psychiatric disorders on blood coagulation and fibrinolysis: a biobehavioral pathway to coronary artery disease? *Psychosom Med* 2001;**63**:531–44.
63. Rajagopalan S, Brook R, Rubenfire M et al. Abnormal brachial artery flow-mediated vasodilation in young adults with major depression. *Am J Cardiol* 2001;**88**:196–8 A7.
64. Severus WE, Littman AB, Stoll AL. Omega-3 fatty acids, homocysteine, and the increased risk of cardiovascular mortality in major depressive disorder. *Harv Rev Psychiatry* 2001;**9**:280–93.
65. Agelink MW, Boz C, Ullrich H et al. Relationship between major depression and heart rate variability. Clinical consequences and implications for antidepressive treatment. *Psychiatry Res* 2002;**113**:139–49.
66. Carney RM, Blumenthal JA, Stein PK et al. Depression, heart rate variability, and acute myocardial infarction. *Circulation* 2001;**104**:2024–8.
67. Gorman JM, Sloan RP. Heart rate variability in depressive and anxiety disorders. *Am Heart J* 2000;**140**:77–83.
68. Lin LY, Wu CC, Liu YB et al. Derangement of heart rate variability during a catastrophic earthquake: a possible mechanism for increased heart attacks. *Pacing Clin Electrophysiol* 2001;**24**:1596–601.
69. Bigger JT, Fleiss JL, Rolnitzky LM et al. The ability of several short-term measures of RR variability to predict mortality after myocardial infarction. *Circulation* 1993;**88**:927–34.
70. van Ravenswaaij-Arts CM, Kollee LA, Hopman JC et al. Heart rate variability. *Ann Intern Med* 1993;**118**:436–47.
71. Hughes JW, Stoney CM. Depressed mood is related to high-frequency heart rate variability during stressors. *Psychosom Med* 2000;**62**:796–803.
72. Blumenthal JA, Wei J. Psychobehavioral treatment in cardiac rehabilitation. *Cardiol Clin* 1993;**11**:323–31.
73. Williams RB, Littman AB. Psychosocial factors: role in cardiac risk and treatment strategies. *Cardiol Clin* 1996;**14**:97–104.
74. Bennett P, Carroll D. Cognitive-behavioural interventions in cardiac rehabilitation. *J Psychosom Res* 1994;**38**:169–82.
75. Sheps DS, Freedland KE, Golden RN et al. ENRICH and SADHART: implications for future biobehavioral intervention efforts. *Psychosom Med* 2003;**65**:1–2.
76. Writing Committee For The EL. Effects of Treating Depression and Low Perceived Social Support on Clinical Events After Myocardial Infarction: The Enhancing Recovery in Coronary Heart Disease Patients (ENRICH) Randomized Trial. *JAMA* 2003;**289**:3106–16.
77. Milani RV, Lavie CJ. Prevalence and effects of cardiac rehabilitation on depression in the elderly with coronary heart disease. *Am J Cardiol* 1998;**81**:1233–6.
78. Ziegelstein RC. Depression in patients recovering from a myocardial infarction. *JAMA* 2001;**286**:1621–7.
79. Turner SC, Bethell HJ, Evans JA et al. Patient characteristics and outcomes of cardiac rehabilitation. *J Cardiopulm Rehabil* 2002;**22**:253–60.
80. Lavie CJ, Milani RV, Cassidy MM et al. Effects of cardiac rehabilitation and exercise training programs in women with depression. *Am J Cardiol* 1999;**83**:1480–3 A7.
81. Blanchard CM, Rodgers WM, Courneya KS et al. Self-efficacy and mood in cardiac rehabilitation: should gender be considered? *Behav Med* 2002;**27**:149–60.
82. Glazer KM, Emery CF, Frid DJ et al. Psychological predictors of adherence and outcomes among patients in cardiac rehabilitation. *J Cardiopulm Rehabil* 2002;**22**:40–6.
83. Bigger JT, Giardina EG, Perel JM et al. Cardiac antiarrhythmic effect of imipramine hydrochloride. *N Engl J Med* 1977;**296**:206–8.
84. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction: preliminary report. *N Engl J Med* 1989;**321**:406–12.
85. Giardina EG, Barnard T, Johnson L et al. The antiarrhythmic effect of nortriptyline in cardiac patients with ventricular premature depolarizations. *J Am Coll Cardiol* 1986;**7**:1363–9.
86. Raeder EA, Zinsli M, Burckhardt D. Effect of maprotiline on cardiac arrhythmias. *Br Med J* 1979;**2**:102.
87. Raeder EA, Burckhardt D, Neubauer H et al. Long-term tri- and tetra-cyclic antidepressants, myocardial contractility, and cardiac rhythm. *Br Med J* 1978;**2**:666–7.
88. Rasmussen SL, Overo KF, Tanghoj P. Cardiac safety of citalopram: prospective trials and retrospective analyses. *J Clin Psychopharmacol* 1999;**19**:407–15.
89. Nelson JC, Kennedy JS, Pollock BG et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. *Am J Psychiatry* 1999;**156**:1024–8.
90. Glassman AH, O'Connor CM, Califf RM et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. *JAMA* 2002;**288**:701–9.
91. Tucker P, Adamson P, Miranda R Jr et al. Paroxetine increases heart rate variability in panic disorder. *J Clin Psychopharmacol* 1997;**17**:370–6.
92. McFarlane A, Kamath MV, Fallen EL et al. Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. *Am Heart J* 2001;**142**:617–23.
93. Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. *Am J Med* 2000;**108**:2–8.
94. Meier CR, Schlienger RG, Jick H. Use of selective serotonin reuptake inhibitors and risk of developing first-time acute myocardial infarction. *Br J Clin Pharmacol* 2001;**52**:179–84.
95. van den Brink RH, van Melle JP, Honig A et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial Infarction and Depression-Intervention Trial (MIND-IT). *Am Heart J* 2002;**144**:219–25.
96. Frasure-Smith N, Lesperance F. Depression — a cardiac risk factor in search of a treatment. *JAMA* 2003;**289**:3171–3.
97. Frasure-Smith N, Lesperance F. Depression and other psychological risks following myocardial infarction. *Arch Gen Psychiatry* 2003;**60**:627–36.
98. Linde K, Ramirez G, Mulrow CD et al. St John's wort for depression — an overview and meta-analysis of randomised clinical trials. *BMJ* 1996;**313**:253–8.
99. Philipp M, Kohnen R, Hiller KO. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. *BMJ* 1999;**319**:1534–8.

100. Woelk H. Comparison of St John's wort and imipramine for treating depression: randomised controlled trial. *BMJ* 2000;**321**:536–9.
101. Effect of *Hypericum perforatum* (St John's wort) in major depressive disorder: a randomized controlled trial. *JAMA* 2002;**287**:1807–1814.
102. Shelton RC, Keller MB, Gelenberg A et al. Effectiveness of St John's wort in major depression: a randomized controlled trial. *JAMA* 2001;**285**:1978–86.
103. Johne A, Brockmoller J, Bauer S et al. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (*Hypericum perforatum*). *Clin Pharmacol Ther* 1999;**66**:338–45.
104. Durr D, Stieger B, Kullak-Ublick GA et al. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. *Clin Pharmacol Ther* 2000;**68**:598–604.
105. Henderson L, Yue QY, Bergquist C et al. St John's wort (*Hypericum perforatum*): drug interactions and clinical outcomes. *Br J Clin Pharmacol* 2002;**54**:349–56.
106. Ernst E. St John's Wort supplements endanger the success of organ transplantation. *Arch Surg* 2002;**137**:316–9.
107. Ruschitzka F, Meier PJ, Turina M et al. Acute heart transplant rejection due to Saint John's wort. *Lancet* 2000;**355**:548–9.
108. Valli G, Giardina EG. Benefits, adverse effects and drug interactions of herbal therapies with cardiovascular effects. *J Am Coll Cardiol* 2002;**39**:1083–95.
109. De Smet PA. Herbal remedies. *N Engl J Med* 2002;**347**:2046–56.